Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Albumin-bound Paclitaxel vs Taxanes in Breast Cancer
NCT05287308Not yet recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Mar 2022
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of paclitaxel in breast cancer (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: 5-year Invasive Disease-Free Survival rate. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05287308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05287308.